Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of LY2189265 on Ambulatory Blood Pressure and Heart Rate in Type 2 Diabetes
2010-019581-82Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dulaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in mean 24-hour systolic blood pressure at 16 weeks. Started May 2010; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-019581-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019581-82.